Apogee Therapeutics
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Massachusetts, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
221 Crescent St, Waltham, Massachusetts,...Phone Number
(650) 394-5230Website
www.apogeetherapeutics.comRevenue
-Stock Symbol
APGEIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
4
1
2
1
2
1
About Apogee Therapeutics
Apogee Therapeutics is a clinical-stage biotechnology company, focused on developing differentiated, best-in-class antibody therapies for inflammatory and immunology (I&I) diseases, including atopic dermatitis, asthma, and COPD. Based in Waltham, MA, Apogee aims to create longer-acting, more effective treatments to reduce injection frequency for patients.Explore more
Apogee Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
LO
Senior VP, Tax
NK
Vice President, Investor Relations
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Apogee Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Apogee Therapeutics has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Apogee Therapeutics recently announced quarterly report
Click to see if Apogee Therapeutics had a recent Job posting/layoffs
Check if Apogee Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Apogee Therapeutics
Apogee Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Apogee Therapeutics launches new products
Check out if Apogee Therapeutics is spiking on competitors!
Recommended Actions
Find VP level buyers at Apogee Therapeutics
Find more new buyers
Compare Similar Companies to Apogee Therapeutics
Compare insights from companies similar to Apogee Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Apogee Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Apogee Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Apogee Therapeutics.
Apogee Therapeutics financials insights
Gather financial insights about Apogee Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Series B
$149M
2026
Unspecified
$1.3B
Apogee Therapeutics Tech Stack
A closer look at the technologies used by Apogee Therapeutics
See more technologies
Most Recent Scoops
Mergers & Acquisitions (M&A)
Mergers & Acquisitions, Acquisitions, Mergers
Project
Apogee Therapeutics has validated its dose optimization approach for zumilokibart through phase IIb data in atopic dermatitis, reporting top-line results of 65% EASI 75 (over 40% placebo-adjusted), with both EASI 90 and IGA 0/1 in the mid-40s on a top-line basis and mid-30s on a placebo-adjusted basis.
Pharmaceuticals
Project
Apogee Therapeutics is currently running a head-to-head trial of APG279 its IL-13 OX40 ligand fixed-dose combination versus DUPIXENT in approximately 86 patients randomized 1-to-1, with capital allocation for further development contingent on achieving at least a 15-to-20-point delta versus DUPIXENT in the study.
Research & Development, Pharmaceuticals, Clinical Operations
Project
Apogee Therapeutics has established an optimized dose, enabling expansion into additional indications including prurigo nodularis (PN), bullous pemphigoid (BP), and chronic spontaneous urticaria (CSU) without repeating dose-range finding.
Medical Research, Pharmaceuticals
Person-Based
Events
Apogee Therapeutics News & Media
Shareholder Alert: Ademi LLP investigates whether Apogee Therapeutics is obtaining a Fair Price for Public Shareholders
MILWAUKEE, July 02, 2026 (GLOBE NEWSWIRE) -- Ademi LLP is investigating Apogee (NASDAQ: APGE) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with CRH.AbbVie Rounds Out Immunology Offerings With Biotech Acquisition - Powder & Bulk Solids
The pharmaceutical giant strengthens its immunology portfolio with the biotech purchase, positioning it for leadership in inflammatory disease treatment.Stock Market Today, June 22: Apogee Therapeutics Soars on AbbVie Cash Buyout Offer
On June 22, 2026, Apogee Therapeutics shares surged as investors reacted to AbbVie's proposed acquisition terms.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Apogee Therapeutics
Sign Up For FreeTo access detailed company insights
Apogee Therapeutics is a clinical-stage biotechnology company, focused on developing differentiated, best-in-class antibody therapies for inflammatory and immunology (I&I) diseases, including atopic dermatitis, asthma, and COPD. Based in Waltham, MA, Apogee aims to create longer-acting, more effective treatments to reduce injection frequency for pa... Read More
